Stockpolly
Search
NMRA · NASDAQ · Biotechnology

Neumora Therapeutics (NMRA)

Develops precision medicines for brain diseases using neuroscience and data science.

$1.38
At close+0.04 (+3.38%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000005000
Gross profit00000000−5000
575060647763715453585342
Research & development423946496146523941453929
151114151617191512141413
General & administrative15014151617191512141413
Operating income−57−50−60−64−77−63−71−54−58−58−53−42
4−586544311−1−1−1
Interest income466544322111
Interest expense000000001222
Other non-operating income058−6−5−4−4−3−1−2−1−10
Income before tax−53−108−54−59−72−59−68−53−57−59−53−43
Income tax expense000000000000
Net income from continuing operations−53−109−54−59−73−59−68−53−57−59−53−43
Net income−53−109−54−59−73−59−68−53−57−59−53−43
EPS, basic−$0.34−$0.68−$0.34−$0.37−$0.45−$0.37−$0.42−$0.33−$0.35−$0.35−$0.30−$0.23
EPS, diluted−$0.34−$0.68−$0.34−$0.37−$0.45−$0.37−$0.42−$0.33−$0.35−$0.35−$0.30−$0.23
Weighted average shares, basic155159158159160161161162162163180185
Weighted average shares, diluted155159158159160161161162162163180185
EBITDA−57−108−54−58−72−59−68−53−56−57−52−42
Depreciation & amortization000000000000
EBIT−57−108−54−59−72−59−68−53−56−57−52−42